MUMBAI, India & NAPLES, Fla., May 5, 2026
Lupin Limited, a global pharmaceutical leader, has announced that it has received U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for Glycerol Phenylbutyrate Oral Liquid, 1.1 g/mL, a generic equivalent of Ravicti®, indicated for the chronic management of urea cycle disorders (UCDs). This approval marks a significant step in expanding access to life-sustaining therapies for rare metabolic disorders, while reinforcing Lupin’s growing presence in the U.S. generics market and specialty pharma segment.
FDA Approval Strengthens Lupin’s Generics Portfolio
The FDA approval confirms that Lupin’s Glycerol Phenylbutyrate Oral Liquid is bioequivalent to the reference listed drug Ravicti®, ensuring comparable safety, efficacy, and quality standards. The drug is indicated for patients with urea cycle disorders, a group of rare genetic conditions characterized by the body’s inability to eliminate ammonia effectively, leading to potentially life-threatening complications if left untreated.
This approval aligns with Lupin’s strategy to expand its complex generics and specialty pharmaceutical portfolio, particularly in areas with high unmet medical need and limited treatment options. The product is designed for patients whose condition cannot be adequately managed through dietary protein restriction or amino acid supplementation alone, making it a critical therapeutic option in long-term disease management.
By securing FDA approval through the ANDA pathway, Lupin demonstrates its ability to meet stringent regulatory requirements, including Good Manufacturing Practice (GMP) compliance, quality assurance, and bioequivalence standards, which are essential for successful entry into regulated markets such as the United States.
Advertisement
Targeted Therapy Integration with Diagnostic Innovation
VEPPANU™ (vepdegestrant) is a PROteolysis TArgeting Chimera (PROTAC) therapy designed to selectively degrade the estrogen receptor, offering a novel treatment option for patients with ESR1-mutated tumors. The integration of Guardant360 CDx as a companion diagnostic ensures that patients most likely to benefit from this therapy are accurately identified, reinforcing the importance of biomarker-driven treatment approaches in oncology.
This approval marks Guardant Health’s third ESR1 companion diagnostic approval and expands the clinical utility of its platform to 26 companion diagnostic indications across multiple tumor types, including lung, breast, and colorectal cancers. The growing adoption of such diagnostics reflects the increasing importance of genomic profiling and targeted therapy alignment in improving patient outcomes and advancing precision medicine.
Addressing Rare Disease Burden with Cost-Effective Therapies
Urea cycle disorders are rare but serious metabolic conditions that require continuous medical management to prevent the accumulation of toxic ammonia levels in the blood. Therapies like Glycerol Phenylbutyrate play a crucial role in nitrogen waste removal, helping patients maintain metabolic balance and reduce the risk of complications such as neurological damage and hospitalization.
The availability of a generic alternative to Ravicti® is expected to improve treatment accessibility and affordability, particularly in the U.S., where the reference product recorded annual sales of approximately USD 337 million (IQVIA MAT December 2025). The introduction of Lupin’s product is likely to increase market competition, potentially lowering costs and improving access for patients requiring long-term therapy.
This development reflects a broader trend in the pharmaceutical industry, where generic drug approvals play a vital role in enhancing healthcare affordability while maintaining high standards of therapeutic quality. It also underscores the importance of regulatory pathways such as ANDA in accelerating the availability of essential medicines.
Strategic Growth in Global Pharma and Regulatory Excellence
Lupin’s FDA approval further strengthens its position as a global pharmaceutical manufacturer with a strong regulatory track record, supported by 15 manufacturing facilities and 7 research centers worldwide. The company’s focus on complex generics, biotechnology products, and active pharmaceutical ingredients (APIs) enables it to address diverse therapeutic areas, including central nervous system, cardiovascular, respiratory, and rare diseases.
The approval also highlights the company’s commitment to quality-driven manufacturing and compliance with global regulatory standards, which are critical for maintaining competitiveness in highly regulated markets. Lupin’s integrated approach, combining research, development, manufacturing, and commercialization, allows it to deliver high-quality, affordable medicines to over 100 markets globally.
As healthcare systems continue to emphasize cost containment and patient access, the role of companies like Lupin in delivering safe, effective, and affordable generic therapies becomes increasingly important. This approval not only supports patients with rare diseases but also contributes to the sustainability of healthcare systems through increased competition and innovation in generics.
Implications for the Pharmaceutical Industry
The FDA approval of Lupin’s Glycerol Phenylbutyrate Oral Liquid underscores the importance of generic drug development in addressing unmet medical needs and improving healthcare accessibility. It also reflects the growing significance of regulatory compliance, bioequivalence studies, and manufacturing excellence in ensuring successful product approvals.
As the pharmaceutical industry evolves, the continued expansion of generic and specialty drug portfolios will play a key role in balancing innovation with affordability, particularly in rare disease segments where treatment options remain limited. Lupin’s latest approval demonstrates its ability to contribute meaningfully to this landscape, reinforcing its position as a trusted global pharmaceutical provider.
Source: Lupin press release
